Claims for Patent: 7,601,888
✉ Email this page to a colleague
Summary for Patent: 7,601,888
Title: | Nucleic acid constructs and methods for producing altered seed oil compositions |
Abstract: | The present invention is in the field of plant genetics and provides recombinant nucleic acid molecules, constructs, and other agents associated with the coordinate manipulation of multiple genes in the fatty acid synthesis pathway. In particular, the agents of the present invention are associated with the simultaneous enhanced expression of certain genes in the fatty acid synthesis pathway and suppressed expression of certain other genes in the same pathway. Also provided are plants incorporating such agents, and in particular plants incorporating such constructs where the plants exhibit altered seed oil compositions. |
Inventor(s): | Fillatti; Joanne J. (Davis, CA), Bringe; Neal A. (St. Charles, MO), Dehesh; Katayoon (Vacaville, CA) |
Assignee: | Monsanto Technology L.L.C. (St. Louis, MO) |
Application Number: | 10/393,347 |
Patent Claims: | 1. A soybean seed exhibiting an oil composition comprising 55 to 80% by weight oleic acid and 8% or less by weight saturated fatty acids, wherein said seed comprises a
recombinant nucleic acid molecule comprising a first set of DNA sequence that is capable, when expressed in a host cell, of suppressing the endogenous expression of FAD2- 1A and FATB, wherein said sequence comprises (i) at least 50 contiguous nucleotides
of an intron of FAD2-1A; and (ii) a sequence selected from the group consisting of at least 50 contiguous nucleotides of a nucleic acid sequence at least 95% identical to SEQ ID NO:36, at least 50 contiguous nucleotides of a nucleic acid sequence at
least 95% identical to SEQ ID NO:37, and combinations thereof.
2. The soybean seed of claim 1, wherein said at least 50 contiguous nucleotides of an intron of FAD2-1A is at least 100 contiguous nucleotides of a FAD2-1A intron 1. 3. The soybean seed of claim 1, wherein said recombinant nucleic acid molecule further comprises a FATB transit sequence. 4. The soybean seed of claim 2, wherein said at least 100 contiguous nucleotides of a FAD2-1A intron 1 is at least 95% identical to 100 contiguous nucleotides of SEQ ID NO: 1. 5. The soybean seed of claim 1, further comprising a second set of DNA sequence that is capable, when expressed in a host cell, of increasing expression of a beta-ketoacyl-ACP synthase IV and/or a delta-9 desaturase. 6. The soybean seed of claim 1 comprising 65 to 80% oleic acid and 2 to 8% saturated fatty acids. 7. The soybean seed of claim 1 comprising 3 to 6% saturated fatty acids. 8. The soybean seed of claim 6 comprising 65 to 75% oleic acid. 9. The soybean seed of claim 1 comprising 60 to 70% oleic acid. 10. The soybean seed of claim 1, wherein said first set of DNA sequence comprises at least 100 contiguous nucleotides at least 95% to SEQ ID NO:36. 11. The soybean seed of claim 1, wherein said first set of DNA sequence comprises at least 100 contiguous nucleotides at least 95% to SEQ ID NO:37. 12. The soybean seed of claim 1, wherein said first set of DNA sequence comprises at least 100 contiguous nucleotides at least 95% to SEQ ID NO:36 and at least 100 contiguous nucleotides at least 95% to SEQ ID NO:37. |
Details for Patent 7,601,888
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | ⤷ Try a Trial | 2022-03-21 |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | ⤷ Try a Trial | 2022-03-21 | |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | Injection | 103132 | ⤷ Try a Trial | 2022-03-21 | |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.